Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) [1] and programmed death-ligand 1/programmed death 1 (PD-L1/PD1) targeting immunotherapy used in combination with or without chemotherapy has been successful [2], the underlying mechanisms leading to poor survival or even unresponsiveness to these therapies in patients with lung adenocarcinoma remain to be elucidated. This evidence concerns the gene EGFR and lung adenocarcinoma.